Pharmacology/Pharmaceutical Industry
Review | The prevention and treatment of nausea and vomiting during tumor therapy.
5 Sep, 2022 | 14:23h | UTCThe Prevention and Treatment of Nausea and Vomiting During Tumor Therapy – Deutsches Ärzteblatt International
Related:
SEOM clinical guideline emesis (2021) – Clinical and Translational Oncology
Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)
2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.
2 Sep, 2022 | 13:17h | UTCNews Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology
Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD
Commentary on Twitter
📢 ACC releases Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
Read more: https://t.co/WDOSPgQ1bx #ACCClinicalDoc pic.twitter.com/nt8S2pdBgD
— American College of Cardiology (@ACCinTouch) August 25, 2022
Review | Covid-19 vaccines — immunity, variants, boosters.
1 Sep, 2022 | 11:57h | UTCCovid-19 Vaccines — Immunity, Variants, Boosters – New England Journal of Medicine
Study Commentary | Zinc for the prevention or treatment of respiratory tract infections: a new systematic review.
1 Sep, 2022 | 11:46h | UTC
Study shows dentists should give antibiotics to high-risk patients to help prevent infectious endocarditis.
1 Sep, 2022 | 11:43h | UTCOriginal Study: Antibiotic Prophylaxis Against Infective Endocarditis Before Invasive Dental Procedures – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: UK dentists should give antibiotics to patients at risk of heart infection – study – The Guardian
Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.
31 Aug, 2022 | 11:51h | UTC
#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.
30 Aug, 2022 | 12:16h | UTCNews Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology
Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.
30 Aug, 2022 | 11:59h | UTCAcute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
Scoping review of randomized trials with discontinuation of medicines in older adults.
26 Aug, 2022 | 13:16h | UTCScoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults – JAMDA
Retrospective Cohort Study | Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.
25 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i
— NEJM (@NEJM) August 24, 2022
USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.
24 Aug, 2022 | 14:21h | UTCEditorials:
Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA
Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA
Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN
Systematic Review | Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia.
24 Aug, 2022 | 14:10h | UTCRelated:
Commonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane
How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative
Anticholinergic drugs and risk of dementia: case-control study – The BMJ
WHO Guidance | Behavioral and social drivers of vaccination: tools and practical guidance for achieving high uptake.
22 Aug, 2022 | 12:13h | UTC
RCT | Metformin, Ivermectin, and Fluvoxamine are not beneficial for obese outpatients with Covid-19.
18 Aug, 2022 | 13:00h | UTCEditorial: Time to Stop Using Ineffective Covid-19 Drugs – New England Journal of Medicine
Commentary on Twitter
In this trial involving overweight or obese outpatients with Covid-19, investigators found that none of three repurposed drugs (metformin, ivermectin, and fluvoxamine) reduced the risk of serious disease. https://t.co/8sd6R7CDK6 pic.twitter.com/bPZ6zeuZSA
— NEJM (@NEJM) August 17, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
AAP Updated Clinical Report | The use of systemic and topical fluoroquinolones.
17 Aug, 2022 | 14:19h | UTCThe Use of Systemic and Topical Fluoroquinolones – Pediatrics
M-A | Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials.
17 Aug, 2022 | 14:02h | UTC
Commentary on Twitter
Immunotherapy was associated with improved the quality of life of patients with advanced cancer, according to results of this comprehensive meta-analysis and systematic review of 34 RCTs of immune checkpoint inhibitors. https://t.co/uSLFT3Nuww
— JAMA Network Open (@JAMANetworkOpen) August 16, 2022
UK approves updated Moderna vaccine targeting Omicron variant.
16 Aug, 2022 | 13:49h | UTCUK approves updated Moderna vaccine targeting Omicron variant – Associated Press/MedicalXpress
See also: Covid: UK first country to approve dual-strain vaccine – BBC
Harmonization of American and European hypertension guidelines: comparisons, reflections, and recommendations.
12 Aug, 2022 | 15:19h | UTCHarmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations – European Heart Journal (also available at Circulation)